Background
swapnil hiremath
From single shots to strategy: How CAPTIVATE is ...

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Background
Cristina Adriana Popa
Are E-Nudges Enough to Push Guideline-Based CKD ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

Are E-Nudges Enough to Push Guideline-Based CKD Therapy?
Background
Brian Rifkin
STAMP of Approval: Tacrolimus vs MMF in ...

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Background
swapnil hiremath
Double Trouble: ddAVP and the Bleeding Biopsy

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

Double Trouble: ddAVP and the Bleeding Biopsy

steroids

IgA and steroids: the saga continues

Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?